AU3206999A - Novel gene that is amplified and overexpressed in cancer and methods of use thereof - Google Patents
Novel gene that is amplified and overexpressed in cancer and methods of use thereofInfo
- Publication number
- AU3206999A AU3206999A AU32069/99A AU3206999A AU3206999A AU 3206999 A AU3206999 A AU 3206999A AU 32069/99 A AU32069/99 A AU 32069/99A AU 3206999 A AU3206999 A AU 3206999A AU 3206999 A AU3206999 A AU 3206999A
- Authority
- AU
- Australia
- Prior art keywords
- overexpressed
- cancer
- amplified
- methods
- novel gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7964998P | 1998-03-27 | 1998-03-27 | |
US60079649 | 1998-03-27 | ||
PCT/US1999/006633 WO1999050408A1 (en) | 1998-03-27 | 1999-03-26 | Novel gene that is amplified and overexpressed in cancer and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
AU3206999A true AU3206999A (en) | 1999-10-18 |
Family
ID=22151909
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU32069/99A Abandoned AU3206999A (en) | 1998-03-27 | 1999-03-26 | Novel gene that is amplified and overexpressed in cancer and methods of use thereof |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU3206999A (en) |
WO (1) | WO1999050408A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10315834A1 (en) * | 2003-03-31 | 2004-11-18 | Hinzmann, Bernd, Dr. | Human nucleic acid sequences from pancreatic carcinomas |
ES2300156B1 (en) * | 2003-10-10 | 2009-05-01 | Progenika Biopharma, S.A. | METHODS FOR IN VITRO AND PRONOSTIC IN VITRO DIAGNOSIS OF THE CANCER OF PANCREAS AND FOR THE DEVELOPMENT OF PHARMACOS AGAINST CANCER OF PANCREAS. |
-
1999
- 1999-03-26 AU AU32069/99A patent/AU3206999A/en not_active Abandoned
- 1999-03-26 WO PCT/US1999/006633 patent/WO1999050408A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO1999050408A1 (en) | 1999-10-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU5481000A (en) | Combination cancer therapy comprising adenosine and deaminase enzyme inhibitor | |
AU1047901A (en) | Methods of genetic cluster analysis and use thereof | |
AU1939801A (en) | In situ bioreactors and methods of use thereof | |
AU6340600A (en) | Telomerase inhibitors and methods of their use | |
AU2309700A (en) | Oligonucleotide array and methods of use | |
AU9334998A (en) | Processing and use of carbide lime | |
AU4803997A (en) | Polymorphisms and new genes in the region of the human hemochromatosis gene | |
AU2002356898A1 (en) | Gene amplification and overexpression in cancer | |
AU2002257050A1 (en) | Nucleic acid and corresponding protein entitled 125p5c8 useful in treatment and detection of cancer | |
AUPQ201499A0 (en) | Treatment of inflammatory and malignant diseases | |
AU2238499A (en) | Androgen-metabolic gene mutations and prostate cancer risk | |
AU2001285018A1 (en) | Nucleic acids and corresponding proteins entitled 83p2h3 and catrf2e11 useful in treatment and detection of cancer | |
AU2796799A (en) | Amplification of gene transfer and gene therapy by controlled replication | |
AU3206999A (en) | Novel gene that is amplified and overexpressed in cancer and methods of use thereof | |
AU5597500A (en) | Streptavidin expressed gene fusions and methods of use thereof | |
WO2002083917A8 (en) | Nucleic acid and corresponding protein entitled 161p5c5 useful in treatment and detection of cancer | |
AU1678900A (en) | A novel liposomal formulation useful in treatment of cancer and other proliferation diseases | |
AU9018598A (en) | Prognostic compositions for prostate cancer and methods of use thereof | |
AU7954500A (en) | Method of in vitro culture of lymphocytes and gene therapy compositions | |
AU2002211690A1 (en) | Altered hox and wnt7a expression in human lung cancer | |
AU1856297A (en) | Lyst1 and lyst2 gene compositions and methods of use | |
AU2584699A (en) | Immediate early genes and methods of use therefor | |
AU6629298A (en) | Interactions of skn7 gene and its use in assay methods | |
AU6653698A (en) | Use of the p-ten suppressor gene in diagnosis and treatment of cancer | |
AU2001297571A1 (en) | Detection and treatment of prostate cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |